Engineered Silkworms Spin Spider Silk as Biotech Firm Targets Commercial Scale
MWN-AI** Summary
Kraig Biocraft Laboratories (OTCQB: KBLB), a biotechnology firm specializing in genetically engineered organisms, is advancing towards commercial production of spider silk using engineered silkworms. This initiative involves the deployment of one million genetically modified silkworm eggs at production sites in Vietnam, aiming for a monthly output of around 10 metric tons of spider-silk cocoons. Known for its unmatched strength and elasticity, spider silk has been difficult to produce in mass quantities, primarily due to the territorial nature of spiders.
Kraig Labs' innovative approach allows these modified silkworms to spin silk fibers that integrate spider silk proteins, efficiently utilizing traditional sericulture techniques rather than complex industrial systems. The company is already preparing to initiate pilot programs with several undisclosed global brands, marking a key step towards the commercialization of this sustainable material.
Historically, Kraig Labs integrated spider silk genes into silkworms over a decade ago, and subsequent studies affirmed that their hybrid fibers demonstrated remarkable toughness, competing closely with natural spider silk. This has garnered the attention of both scientific and media circles, including features in notable publications like National Geographic.
The production of genetically engineered materials like spider silk remains rare, yet Kraig Labs' approach represents a significant breakthrough outside of pharmaceuticals, standing alongside examples like ATryn, a therapeutic protein derived from genetically modified goats. Current production includes hybrid fibers, but the company is exploring even more advanced genetic designs, specifically aiming to enable silkworms to produce fibers predominantly composed of spider silk proteins by incorporating sequences from the Darwin's bark spider.
By merging ancient silk production methods with cutting-edge biogenetics, Kraig Labs seeks to transform spider silk from an elusive research material into a commercially viable product.
MWN-AI** Analysis
As Kraig Biocraft Laboratories (OTCQB: KBLB) advances toward commercial-scale production of spider silk via genetically engineered silkworms, investors should carefully consider the potential and risks associated with this biotech innovation. The growing interest in high-performance, sustainable materials makes Kraig an intriguing market prospect.
Kraig has announced a significant scale-up, deploying one million engineered silkworm eggs in Vietnam with the goal of producing approximately 10 metric tons of recombinant spider-silk cocoons monthly. This would be an impressive advancement, as spider silk exhibits exceptional tensile strength and elasticity, outperforming many synthetic materials. The technique developed allows for the use of traditional sericulture methods, reducing reliance on costly industrial reactors.
Market trends indicate a rising demand for sustainable materials across various sectors, from textiles to medical applications. If Kraig seamlessly transitions from lab-based research to operational production, it could place the company in a favorable position to cater to this demand. Initial shipments are reportedly being prepared for pilot programs with global brands, suggesting a level of market readiness that could catalyze growth.
However, risks exist. The commercialization of genetically engineered organisms often faces regulatory hurdles and public scrutiny, which can impede market entry and scaling efforts. Furthermore, Kraig's competition includes both existing materials and other biotech firms exploring similar avenues, which may affect market share.
In conclusion, while Kraig Biocraft Laboratories presents a compelling investment opportunity taking advantage of biotech advances and market demand for sustainable materials, potential investors should remain cautious. Conduct thorough due diligence, considering both the innovative potential of their technology and the inherent risks associated with biotechnological commercial ventures. Consulting with a financial advisor before investing is highly recommended.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- www.247marketnews.com -- A biotechnology company developing genetically engineered silkworms says it’s moving toward commercial production of spider silk, a material long sought by researchers for its unusual combination of strength and elasticity.
Kraig Biocraft Laboratories (OTCQB: KBLB) deployed one million genetically engineered silkworm eggs across multiple production facilities in Vietnam as part of a Spring scale-up effort that could eventually produce around 10 metric tons of recombinant spider-silk cocoons per month.
Spider silk has attracted scientific interest for decades because of its mechanical properties. By weight, the fiber can be stronger than steel and tougher than many high-performance synthetic materials. The challenge has been viable mass production, since spiders cannot be farmed easily due to their territorial behavior.
The company’s approach modifies domesticated silkworms so they spin fibers incorporating the desired spider-silk proteins. The insects retain their natural spinning process, allowing the fiber to be produced using traditional sericulture methods rather than industrial reactors.
Kraig Labs says it is preparing initial shipments of the biodegradable recombinant Spider Silk material to several unannounced global brands as part of pilot development programs and first commercial deliveries.
From lab research to industrial production
Kraig Labs first reported integrating spider-silk genes into silkworms more than a decade ago. The work was later described in a peer-reviewed study in the Proceedings of the National Academy of Sciences, which reported that composite fibers produced by transgenic silkworms were tougher than conventional silkworm silk and approached the toughness of natural dragline spider silk.
The research drew widespread attention at the time, including coverage in science publications and mainstream media following a press conference at the University of Notre Dame announcing the breakthrough.
The technology is still attracting interest from the leading authorities, as the March issue of National Geographic examines efforts to commercialize spider silk and highlights genetically engineered silkworms as a potential pathway to scalable production.
Rare precedent for engineered animal products
Commercial products derived from genetically engineered animals remain uncommon.
One example is ATryn, a therapeutic antithrombin protein produced in the milk of genetically modified goats. The drug was approved in Europe in 2006 and by the U.S. Food and Drug Administration in 2009 after more than two decades of development. Sanofi later acquired the developer, Genzyme, for $20.1 billion in 2011.
Kraig’s platform differs from pharmaceutical production because the silkworm directly produces a structural fiber rather than a purified biological compound.
If the company succeeds in maintaining industrial-scale production, it would represent one of the few examples of a transgenic animal system used for commercial manufacturing outside pharmaceuticals.
Hybrid fibers today, purer silk tomorrow
Current production fibers are hybrid composites combining traditional silkworm silk proteins with spider-silk proteins. Kraig Labs stated that laboratory testing of the material has shown tensile strengths for some samples approaching 1.8 gigapascals and elasticity above 38%.
The company is also exploring a more ambitious genetic design using sequences from the Darwin’s bark spider, known for producing some of the toughest natural silk fibers measured. That research aims to replace the silkworm’s native silk genes with spider-silk genes, potentially allowing the insects to produce fibers composed largely of spider silk proteins. Results from that work have not yet been announced.
Ancient industry meets modern genetics
Sericulture is the cultivation of silkworms for silk production, which dates back more than a thousand years and remains a major industry in Asia.
By combining that historical production system with modern gene-editing techniques, Kraig is attempting to turn spider silk from a laboratory material into a commercially manufactured fiber.
For more information about Kraig Labs’ spider silk technology and partnership opportunities, visit www.kraiglabs.com
About 24/7 Market News
In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247marketnews.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
About Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB)
Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Kraig Labs”) is a biotechnology company focused on the development and commercialization of advanced biomaterials through genetic engineering. The company is best known for its work in producing recombinant spider silk using genetically engineered silkworms, an approach designed to overcome the long-standing challenges of harvesting spider silk at scale.
With growing interest in sustainable and high-performance materials, Kraig Labs is positioning itself at the intersection of biotechnology and advanced materials science, seeking to deliver novel fiber solutions to global markets.
Kraig Labs was the recent cover feature of the March 2026 edition of National Geographic, https://www.nationalgeographic.com/science/article/spider-silk-silkworm-genetic-engineering. Please go to www.kraiglabs.com for further information.
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is a third-party media provider that owns KBLB shares, which are on deposit and may be sold at the editor’s discretion, and has been compensated for providing ongoing KBLB market outreach and other services.. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions.
For further information, please visit 247marketnews.com or https://go.247marketnews.com/kblb-disclosure/
CONTACT:
24/7 Market News
Editor@247marketnews.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
FAQ**
Sure! Here are four questions regarding Kraig Biocraft Labs Inc (KBLB) from the article:
1. How does Kraig Biocraft Labs Inc (KBLB) plan to ensure the viability of commercial production of spider silk using genetically engineered silkworms, especially in terms of scaling up production to 10 metric tons per month?
2. Given the historical challenges of harvesting spider silk, how does Kraig Biocraft Labs Inc (KBLB) differentiate its approach from previous attempts in the industry?
3. What potential markets and applications does Kraig Biocraft Labs Inc (KBLB) envision for their spider silk fibers, considering their unique mechanical properties?
4. How does the partnership strategy of Kraig Biocraft Labs Inc (KBLB) with global brands factor into their pilot development programs and initial commercial deliveries of spider silk?
**MWN-AI FAQ is based on asking OpenAI questions about Kraig Biocraft Labs Inc (OTC: KBLB).
NASDAQ: KBLB
KBLB Trading
0.86% G/L:
$0.117 Last:
1,559,145 Volume:
$0.12 Open:
